Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP). The focus of Upstream Bio is to maximize verekitug’s unique attributes to address the substantial unmet needs of patients with severe asthma and CRSwNP that are underserved by today’s standard of care. Beyond these initial indications, Upstream Bio believes verekitug has broad potential in other inflammatory diseases, and it intends to leverage verekitug’s differentiated attributes to develop it as a potential therapy for diseases where TSLP signaling has been shown to play a significant role.